Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

PHASE1CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

October 8, 2023

Study Completion Date

October 8, 2023

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL

Gamma-PN3

Inactivated whole-cell pneumococcal vaccine

BIOLOGICAL

Prevenar-13

Licensed polysaccharide conjugate pneumococcal vaccine

BIOLOGICAL

Pneumovax-23

Licensed polysaccharide pneumococcal vaccine

DRUG

Placebo

Saline

Trial Locations (1)

CMAX, Adelaide